Expert Interview
Discussing the potential of Novartis’ Tafinlar (dabrafenib) and Mekinist (trametinib) combo for BRAF V600E mutated low-grade glioma with a pediatric neuro-oncologist.
Ticker(s): NVSInstitution: UT Southwestern
- Professor of Pediatric Hematology and Oncology & Medical Director of Pediatric neuro-oncology at Children's Health at University of Texas Southwestern.
- Manages 15 patients a week with glioma and 4 patients for BRAF V600E-mutated low-grade glioma.
- Research and clinical interests include the development of new therapies for children with brain tumors and cancer survivorship.
Roughly how many pediatric patients do you treat for BRAF V600E-mutated low-grade glioma?
Added By: sara_adminWhat is the current SOC for your pediatric patients with BRAF V600E-mutated low-grade glioma?
Added By: sara_adminWhat is your level of excitement(on a scale from 1 to 10) about the approval of Novartis’ Tafinlar (dabrafenib) and Mekinist (trametinib) combo for BRAF V600E mutated low-grade glioma in kids aged 1 year and up?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
